The growth of breast cancer is highly variable. This is reflected in its clinical course and is a major factor contributing to prognosis. To date, however, methods employed to assess this parameter have had limited success. The opportunity to monitor the clinical growth of primary and metastatic tumours directly occurs infrequently (see Devitt, 1983 ) and more indirect methods of 3H thymidine incorporation (Silvestrini et al., 1974) or flow cytometry (Haag et al., 1984) are complex procedures that are time consuming and not really applicable to routine clinical samples. More recently, a monoclonal antibody Ki67 has been produced which is suggested to react with a nuclear antigen present throughout the cell cycle (GI, S, G2 and M phases) of proliferating cells, but is absent in quiescent (GO) cells (Gerdes et al., 1984a, b) . This antibody can be readily used in an immunocytochemical assay (Gerdes et al., 1986) and its binding has been shown to correlate with the histological classification of non-Hodgkin's lymphomas and with lymph node status (Gerdes et al., 1984a, b) and histological grade of malignancy (Barnard et al., 1987) in breast cancers.
The current study reports our early experience with this marker of cell proliferation in a series of 136 primary breast cancer specimens from a single centre and its correlation with the early recurrence of breast cancer after mastectomy.
Patients and methods
Tumour samples were obtained from 136 unselected primary breast cancer patients at the City Hospital in Nottingham under the care of Professor R.W. Blamey. A simple or subcutaneous mastectomy was undertaken and lymph-node biopsy samples were removed from the lower axilla, from the apex of the axilla and from the internal mammary chain . Patients with tumour cells histologically evident in any node were classified as lymphnode positive. All patients had tumours which were judged clinically to be less than 5cm diameter, and none showed any evidence of distant metastases at presentation. The menopausal status and age at mastectomy of each patient were recorded in addition to tumour size. Histological grade of malignancy was assessed in all tumours by C.W.E. and I.O.E. using a modification of Bloom and Richardson's criteria (Elston et al., 1980) . Tumours were classified I to III with increasing loss of differentiation. The mitotic activity of tumours was assessed by counting the number of mitotic figures in 10 or 20 high power fields around the periphery of the tumour. The divisions I to III corresponded to 0-9, 10-Correspondence: R.I. Nicholson. 19 and >20 mitotic figures per 10 high power fields. All primary breast cancer patients were followed up at 3-monthly intervals for 18 months and 6-monthly thereafter. Recurrent disease that was palpable was confirmed cytologically or histologically. Metastatic disease was confirmed by clinical or radiological examination.
Tissue preparation
Immediately after surgery tumour tissue was snap frozen and stored in liquid nitrogen before transportation to the Tenovus Institute in dry ice. Samples were stored at -70°C until assay, at which time a portion of the frozen tissue was embedded in Tissue-Tek OCT (Miles Scientific, Naperville, IL, USA) and maintained at -70°C. The remainder of the tissue was utilised in the oestrogen receptor enzymeimmunoassay (ER-EIA).
Antibodies and Ki67 staining procedure Cryostat sections (5 um) were cut, mounted on slides coated with tissue adhesive, fixed in acetone (-10 to -25°C) and air dried. Sections were incubated at room temperature with normal goat serum (diluted 1 in 10 with 10mm phosphatebuffered saline (PBS; pH7.2-7.4) for 15min, excess serum was removed and the slides were incubated for a further 45min with mouse monoclonal Ki67 antibody (1.4pgMnl-1; Dakopatts, Denmark). The slides were then rinsed in PBS and reincubated for 30min with a goat-antimouse bridging antibody (4.7 Mg ml -1; Sigma, UK) containing normal human serum (diluted 1 in 50 with PBS), followed, after washing (2 x PBS), with a mouse peroxidase antiperoxidase complex (PAP; diluted 1 in 250 with PBS; Dakopatts, Denmark) for 30 min. A chromogen substrate solution containing hydrogen peroxide (0.06% v/v) and diaminobenzidine 4HC1 (DAB; 0.05% w/v) was added to each specimen for 5min. The reaction of peroxidase in the PAP complex with hydrogen peroxide converts the DAB to a reddish brown product. Sections were immersed in distilled water before counterstaining with Harris's Haematoxylin (1% v/v) for 6min. The slides were then rinsed in tapwater for 5 min, dehydrated in alcohol, cleared in xylene and mounted under coverslips in dibutylpthalate xylene solution.
All specimen evaluation was performed on an Olympus microscope (BH-2) using an ocular magnification of x 40 with an eyepiece grid (Graticules Ltd, UK). Ten to 20 fields per tumour were examined depending on its cellularity (minimum 1,000 tumour cells). Control slides (minus primary antibody) were assessed for non-specific binding before assessing the percentage of tumour cell binding the Ki67 antibody. Tumours were classified as positive where greater than 5% of tumour cells expressed detectable quantities of Ki67. This value was selected since it represented a figure which is in excess of that determined for normal and benign breast tissue. Additionally, tumours were classified as highly positive if they contained 20% or greater of their cells expressing Ki67 immunostaining. This value was chosen because it selected for the highest quadrile of Ki67 values. Areas of normal and benign breast were excluded from the final assessment.
Oestrogen receptor enzymeimmunoassay (ER-EIA) The enzymeimmunoassay for the detection of ER was carried out using an assay kit developed by Abbott Diagnostics (Abbott Laboratories, Chicago, USA). The assay is a solid-phase immunoassay based on a sandwich principal and has been described in detail elsewhere (Nicholson et al., 1986 ). An ER-EIA value of greater or equal to 10fmolpermg protein was taken to signify an ERpositive tumour.
Statistical analysis
Data were analysed using x2 and x2 for trend according to Armitage (1971 Examination of the individual components of tumour grade and Ki67 binding showed a similar association to that described above with Ki67 status and percentage of cells staining, increasing with increasing nuclear abnormalities (Figure 2b ; x2 =6.9, P <0.05; x2 (trend) = 6.9, P <0. Recurrence-free interval Examination of the recurrence-free interval of patients following mastectomy showed that women with Ki67 positive tumours have a less favourable early prognosis than those with Ki67 negative disease and suffer an increased number of recurrences (Figure 4a ). Further stratification of the data according to the number of Ki67 positive cells within breast tumours identified a high rate of recurrence in patients whose tumours contained >20% Ki67 positive cells (Figure 4b and c) . High rates of recurrence were observed in patients whose tumours expressed high amounts of Ki67 immunostaining (> 20% cells stained) irrespective of their lymph-node involvement (Figure 5a and b) or ER-EIA status (Figure 5c and d) . The differences, however, did not reach statistical significance (not illustrated).
Discussion
Several reports have now examined the binding of Ki67 in breast cancer specimens and have observed a significant relationship with the histological grade of malignancy and the mitotic activity of tumours (Barnard et al., 1987; Gerdes et al., 1984b; Lelle et al., 1987) . This association has been confirmed in our series and extended to show, for the first time, that the binding of the Ki67 antibody also correlates with the early recurrence of breast cancer, specifically when large numbers of tumour cells immunostain (> 20% (Baisch & Gerdes, 1987) growth and then falls back to 5-10% at confluence (manuscript in preparation). In this light, the lack of an absolute correlation between Ki67 immunostaining and mitotic activity in our series of breast tumours (Figure 2c ) is most readily accounted for by sampling differences within the study, in that the estimations of these parameters were not performed on the same portion of the tumour (see Materials and methods). In a smaller series of primary breast tumours from the Tenovus/Nottingham series where this has been carried out, a much closer correlation has been achieved (I.O. Ellis, personal communication) .
Interestingly, although similar results to those described above have also been observed using S phase measurements by thymidine labelling (Mayer & Lee, 1980; Tubiana et al., 1981; Meyer et al., 1983; Haag et al., 1984) and cell cycle analysis by flow cytometry (Kallioniemi et al., 1988) with high rates of cell proliferation being associated with a high proportion of short-term relapses, Ki67 immunostaining is much easier to perform than the above techniques and is more suitable for routine use provided that facilities for producing frozen sections are available.
The comparison of Ki67 binding with the important prognostic variable lymph-node staging did not reveal any major association. This result complements the study of Barnard et al. (1987) , but is at slight variance with the data of Lelle et al. (1987) , who suggested that the average number of Ki67 positive cells in breast tumours was slightly higher in (Cooke, 1982) . Interestingly, using a bivariate analysis, Meyer et al. (1983) suggested that the prognostic relevance of ER in predicting the course of the disease following mastectomy was largely dependent on its relationship to proliferative activity, a conclusion also reached by Nicholson et al. (1984) examining the prognostic value of mitotic activity and ER. In this context, it may be significant that while the above studies employed a ligand binding assay (LBA) to detect ER, the current study utilises a highly sensitive enzymeimmunoassay which, although correlating with the LBA (Leclerq et al., 1986) , produces a higher ER positivity rate (Nicholson et al., 1986) . The independence of Ki67 binding and lymph-node staging and tumour size, together with its strong relationship with histological grade of malignancy, may ultimately allow its substitution for the latter characteristic in a prognostic index developed by our group to accurately predict the course of breast cancer in subgroups of patients (Haybittle et al., 1982) . Because of the very variable nature of breast cancer it is clinically useful to regard it as comprising subgroups of patients, some with good prognosis, others with poor prognosis. Since an important determinant of this is undoubtedly the rate of growth of the disease and since sensitivity to hormone and cytotoxic therapy may also be influenced by this feature (Valeriote & Van Putten, 1975 ), Ki67 binding, as an objective measurement of cell proliferation, should significantly aid in the management of the breast cancer patient. Studies to extend this series and compare Ki67 immunostaining with other prognostic variables are currently underway.
